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Introduction
Major mental illnesses are prevalent disorders that contribute 
to a substantial proportion of overall illness burdens. Excluding 
dementias, they occur at a combined lifetime prevalence of nearly 5% 
for psychotic and bipolar disorders and approximately 10% for major 
depressive disorder [1-3]. As largely chronic or recurrent illnesses, 
they carry high risks of disability and early mortality, in addition to 
representing extraordinary direct (care) and indirect (disability) costs 
to society [4-11]. Such disorders particularly during acute dysfunction, 
dangerousness, and with commonly co-occurring general medical 
illness represent the most frequent reason for hospitalization in 
psychiatric units of general hospitals as well as specialized institutions 
[2,3,12-14]. Moreover, the costs would be far larger if not for the major 
diversion of the severely mentally ill to the criminal justice system, 
particularly in the US [15-18]. 
Along with efforts to contain costs associated with general medical 
care, there have been particular efforts to limit costs of treating 
patients with psychiatric disorders [19,20]. Annual costs of care for 
mentally ill persons in the US now exceed $200-billion. This is the 
third highest category of healthcare costs in the nation, tied with 
cancer, and representing a substantial proportion of total national 
health care expenditures, now approaching $4-trillion per year 
[19,21-23]. The largest component of the costs for psychiatric care is 
hospitalization-representing between a quarter and one-third of total 
costs; the remainder is associated with partial-hospital and ambulatory 
care, prescription drugs, and administrative costs [5]. As a leading 
contributor to the costs of care, hospitalization is a target of intense 
scrutiny among insurers, administrators, and others seeking to rein in 
costs of mental health services, while balancing the obligation to meet 
clinical needs [19,20,24]. 
Facilitating efforts to limit costs, modern clinical 
psychopharmacology has helped to provide a relatively efficient and 
cost-effective component of treatment. The rise of pharmacotherapy 
has been associated with less frequent and shorter hospitalizations, 
briefer outpatient visits and less emphasis on lengthy psychotherapies, 
especially for patients with relatively mild or moderate illnesses [25,26]. 
Nevertheless, psychiatric hospitalization, especially of the severely 
mentally ill, has been unavoidable and the costs of hospitalization [and 
incarceration] remain a leading financial strain to individuals, third-
party payers, and society [5,12,27-29]. Efforts to manage costs associated 
with psychiatric illness include increasingly strenuous requirements by 
insurers tending to limit hospital admissions and days per admission 
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and to reduce per-diem reimbursements for prolonged hospitalization 
[24,30,31]. Such efforts appear to be only partly effective, and they 
can complicate efforts to balance clinical needs against administrative 
and financial aims [24]. Moreover, excessively brief hospitalization 
not only risks adverse clinical and social consequences, but also 
increased costs due to re-admissions that reflect inadequate care [24]. 
Alternatives to inpatient care, such as partial-hospital and supervised 
group programs can be helpful and cost-effective, but typically are not 
adequately financially supported by public mental health programs 
or private insurances [24,32-38]. Additional costs associated with 
excessively restricted hospital care include more frequent clinic visits 
and greater utilization of expensive and inefficient emergency services 
[24,36,39,40]. Furthermore, efforts to minimize hospitalization also 
encourage increasingly complex, poorly evaluated, and potentially 
more expensive and less well tolerated pharmacological treatments 
[25,41,42]. 
In the face of the dilemma between demands of cost-control and 
requirements for appropriate clinical care, there is growing interest 
in identifying clinical factors that contribute to the costs of inpatient 
care. Such efforts aim to improve allocation of services that address 
such risk factors, as well as predicting and managing costs associated 
with illnesses that require more intensive treatment [3,11,40,43-
45]. Proposed risk factors for psychiatric hospitalization include 
repeated occurrences or exacerbations of illness, greater overall illness 
severity, disability and poverty, as well as suspected non-adherence to 
recommended treatment [46-53]. 
In this study, we sought to identify clinical factors that affect the 
costs of psychiatric hospitalization in a large, closely evaluated cohort 
of patients with psychotic or major mood disorders during and 
following hospitalizations in a university-affiliated, psychiatric teaching 
hospital. A specific aim was to identify particular clinical and treatment 
characteristics associated with greater utilization and cost of inpatient 
care, based on actual costs rather than on reimbursements derived from 
insurer databases. 
Method
Subjects and data acquisition
We collected data from medical records of 589 consecutive, 
adult patients diagnosed with psychotic or major mood disorders, 
hospitalized in a specialized inpatient unit at a private, non-profit, 
psychiatric teaching hospital between January 2010 and December 
2013. We sought to provide an accurate picture of actual hospitalization 
costs per subject. Information was extracted independently by two 
experienced investigators (MC, GM) and discrepancies were resolved 
by investigator-consensus. The study was reviewed and approved 
for anonymous and aggregate reporting of findings by the hospital’s 
Institutional Review Board. Other findings arising from the present 
cohort have been reported previously [24,54,55]. 
Data collected from medical records included age, sex, discharge 
diagnoses (updated to DSM-5 criteria), socioeconomic and functional 
status including employment and living status, estimated age at first 
psychiatric symptoms and first treatment, estimated total years of 
illness, as well as types and doses of all drugs given within 90 days 
before, as well as during hospitalization and at discharge, and clinically 
estimated adherence with prescribed treatment in the six months prior 
to initial hospitalization. Also recorded were presence or absence of 
substance abuse, smoking status, body-mass index (BMI), pulse rate, 
blood pressure, hematological measures and serum concentrations of 
electrolytes, glucose, hemoglobin-glycosylation, lipids, and markers 
of kidney and liver functions assayed during hospitalization. We also 
noted the number and types of co-occurring general medical disorders 
diagnosed, as well as all testing (including electroencephalographic 
(EEG) and magnetic resonance brain imaging [MRI] methods), 
specialist-consultations, and treatments given during hospitalization, 
and we categorized dispositions at discharge. Costs of each service and 
medicine were developed with the assistance of members of the hospital 
pharmacy and administrative departments. We also considered the 
number and duration of psychiatric admissions to the same hospital 
(hospitalization elsewhere occurred in <1% of cases) over the three-
year period of observation. 
Data analytic procedures
We developed estimates of total costs of care, based on per-diem 
costs of hospitalization plus costs of medical procedures and treatments 
received. Total cost-estimates (thousands of US dollars (USD)/year per 
person) were compared in preliminary bivariate analyses (ANOVA, 
with t-scores, and relative-risk ratios as well as standardized differences 
as Cohen’s d-statistic [difference/SD]) of factors of interest. Multivariate 
linear regression modeling then used cost/person as the dependent 
variable, with covariates preliminarily identified as associated with cost 
entered stepwise. Averages are presented as means ± standard deviation 
(SD) or with 95% confidence interval (CI); results of linear regression 
modeling are reported as slope functions (β) with CI. Statistical 
significance required two-tailed p<0.05, with Bonferroni adjustment 
for testing of multiple individual factors. 
Results
Characteristics of subjects
Study subjects (N=589) averaged 35.7 ± 13.0 [18-68] years of age; 
59.6% were men, and 81.8% were Caucasian. Overall duration of illness 
from onset averaged 12.4 ± 9.68 years, including the three years of 
observation (Table 1). Primary psychiatric diagnoses (DSM-5 criteria) 
ranked: bipolar disorder (36.0%), schizoaffective disorder (18.2%), 
major depressive disorder (14.4%), schizophrenia (13.1%), other 
psychotic disorders (12.6%) and other disorders (5.77%). Initial index 
hospitalizations were first-lifetime admissions for 17.3% of subjects and 
84.3% of these involved psychotic disorders; 36.3% of subjects were 
hospitalized more than once over the three-year period sampled, at an 
average of 0.51 ± 0.29 hospitalizations/person-year, lasting on average 
13.3 ± 12.3 days per admission. Salient characteristics are summarized 
in Table 1. 
Factors associated with hospitalization costs
We compared estimated, annualized total inpatient treatment costs 
per person for each subject over the three years sampled. A total of 21 
factors, individually, were associated with greater costs per person (18 
met the Bonferroni-adjusted significance criterion of p ≤ 0.002, and 
16 of these were not directly related to days/year in hospital; Table 2). 
Comparisons of matched pairs of mean costs/person/year for each 
factor were contrasted by the ratio of costs with the factor present/
absent. In addition, we computed standardized differences (Cohen’s 
d-statistic for each cost-pair [not shown]). These ranged from 2.06 for 
cases involving hospitalization for ≥ 14 days, to 0.26 for the presence of 
a lifetime suicidal act. Since the rate-ratio measures shown correlated 
very closely with values of d-statistic (r=0.998), we report the rate-ratio 
data to indicate the magnitude of cost differences for each covariate 
(Table 2). 
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Total costs of inpatient care per person averaged $9500 (CI: 
8860–10,100) USD/year. As expected, factors most associated with 
greater costs were more hospitalizations and more days hospitalized 
accounting for more than 90% of total costs. Nevertheless, other clinical 
and treatment factors also were significantly associated with higher total 
costs. Notably, these included a diagnosis of non-affective psychotic 
disorder, treatment with clozapine, use of multiple psychotropic drugs 
or multiple antipsychotics per person, two or more general medical 
illnesses and multiple non-psychiatric medicines, and receiving 
electroconvulsive treatment (ECT). In addition, unemployment, age 
initially ≥ 40 years, non-Caucasian race, and discharge to a supervised 
living situation such as a group home (but not living in such a setting 
prior to admission) were associated preliminarily with higher costs. 
Having multiple medical diagnoses, receiving consultations with 
medical or psychiatric specialists, and a relatively large number of 
laboratory tests (excluding EEG and MRI procedures) also were related 
to higher costs. Diagnosis of schizophrenia or schizoaffective disorder 
was associated with greater costs than diagnoses of bipolar disorder or 
major depressive disorder (by 36%) (Table 3), as was lifetime suicidal 
behavior (by 24%). However, an Axis II diagnosis and lack of psychiatric 
hospitalization prior to the index admission were associated with less 
cost. Marital status, sex, and substance abuse were not significantly 
associated with hospitalization costs. Effects of selected factors on costs 
of hospital-care are summarized in Figure 1. 
Multivariate modeling
We employed multivariate linear regression modeling to identify 
factors preliminarily found to be associated with hospital-based costs-
of-care (see Table 2), examining each for significant and independent 
association with costs. The number of days hospitalized/year accounted 
for the highest proportion of total hospitalization costs (94.9% [CI: 
94.0–94.8]). Based on multivariate linear regression modeling, with 
Characteristic Measure
Cases (n, %)
   Men
   Women
589 (100)
351 (59.6)
238 40.4)
Social factors 
   GAF at initial admission
   Married (%)
   Employed (%)
   Pre-admission supervised living (%)
   Discharged to supervised living (%)
28.5 ± 5.73
14.9
36.7
13.6
19.5
Diagnosis (%)
   Bipolar disorder
   Schizoaffective disorder
   Major depressive disorder
   Schizophrenia
   Other psychoses
   Other disorders
36.0
18.2
14.4
13.1
12.6
5.77
Years ill * 12.4 ± 9.68
General medical illnesses
   Subjects affected (n, %)
   Diagnoses/person
345 (58.6)
1.71 ± 2.07
Clinical factors (≤ 6 months; %)
   Substance abuse
   Suicidal ideation or act
58.6
60.1
Treatments (at first discharge)
   ≥ 2 psychotropics (%)
   Psychotropics/person
   Nonpsychotropic medicines/person
   ≥ 2 antipsychotics (%)
   Clozapine (%)
   ECT
69.4
2.08 ± 1.04
2.57 ± 2.54
16.3
9.85
7.13
Psychiatric hospitalization
   Admissions/year
   Days hospitalized/year
   Days/admission
0.51 ± 0.29
6.65 ± 4.97
13.3 ± 12.3
[*] Includes the 3 years of observation  
Table 1: Characteristics of study subjects.
Factor
Cost [$/year × 10–3] vs. Factor
t-score p-value
Present Absent Ratio
>14 Hospital days total 14.4 ± 8.27 4.33 ± 1.49 3.33 20.4 <0.0001
≥ 2 Hospitalizations/3 years 15.3 ± 8.80 6.25 ± 4.83 2.45 16.1 <0.0001
Clozapine given 16.2 ± 11.3 8.77 ± 7.00 1.85 7.12 <0.0001
ECT given 17.0 ± 10.4 8.92 ± 7.31 1.91 6.67 <0.0001
≥ 2 Consultations per admission 11.8 ± 9.29 8.18 ± 6.55 1.44 5.53 <0.0001
≥ 2 Non-psychotropic medicines 10.9 ± 8.78 7.43 ± 5.65 1.47 5.41 <0.0001
Initial hospitalization, first-lifetime 6.25 ± 4.89 10.2 ± 8.18 0.61 4.68 <0.0001
Non-independent living post-hospitalization 12.2 ± 10.1 8.83 ± 7.06 1.38 4.24 <0.0001
Schizophrenia/schizoaffective diagnosis vs. major affective disorder diagnosis 11.1 ± 9.16 8.36 ± 6.41 1.33 4.18 <0.0001
Unemployed 10.5 ± 8.60 7.79 ± 5.85 1.35 4.04 <0.0001
Ill ≥ 10 years total 10.7 ± 6.29 8.18 ± 6.29 1.31 3.97 <0.0001
≥ 2 Medical diagnoses 10.9 ± 8.91 8.47 ± 6.82 1.29 3.78 0.0002
≥ 2 Antipsychotic drugs/admission 12.6 ± 9.11 9.04 ± 7.55 1.39 3.74 0.0002
Age initially ≥ 40 years 11.0 ± 9.21 8.54 ± 6.66 1.29 3.69 0.0002
>2 Psychotropic drugs/admission 11.2 ± 8.71 8.75 ± 7.32 1.28 3.47 0.0006
Psychotic in hospital 10.1 ± 8.26 7.81 ± 6.36 1.29 3.22 0.001
Suicidal act ever 10.7 ± 9.56 8.62 ± 6.24 1.24 3.18 0.002
BMI ≥ 25 kg/m2 10.3 ± 8.34 8.23 ± 6.94 1.25 3.05 0.002
Data are mean ± SD of annualized costs for psychiatric hospital care over 3 years in N=589 patient-subjects [94.2% with psychotic or major affective disorder diagnoses]. 
The overall mean cost/year was 9496 [CI: 8861–10,132] USD]. Factors [n=18] are ranked in descending order of significance, based on a Bonferroni adjusted criterion of 
p ≤ 0.002 [0.05/21] as significant; 16 were not directly related to hospitalization itself. Factors not associated with cost of hospital treatment included: [a] sex, [b] marital 
status, [c] smoking or substance abuse, [d] suicidal ideation within 6 months, [e] inpatient brain MRI or EEG studies, [f] considered poorly adherent to outpatient treatment, 
[g] living non-independently prior to hospitalization, and [h] GAF <30 at initial admission.  
Table 2: Factors associated with total annualized costs of psychiatric inpatient treatment. 
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hospitalizations/year retained as an independent variable, six other 
significantly associated factors ranked [by β with CI]: [a] treatment with 
ECT (β=16.0 (10.3–21.8)), [b] treatment with clozapine (12.5 (7.32–
17.8)), [c] discharge to a supervised living situation (7.02 (3.22–10.8)), 
[d] diagnosis of a non-affective or schizoaffective psychotic disorder 
(3.86 [0.70–7.03]), [e] more specialist consultations in hospital (3.64 
(2.16–5.11)), and [f] more antipsychotic drugs/person in hospital (2.73 
(1.08–4.38); not shown). As expected, factors associated with overall costs 
of inpatient care were also correlated with days hospitalized per year. 
Discussion
The present findings are based on assessments of 589 patients 
diagnosed with a DSM-5 psychotic or major affective disorder, treated 
and followed at a university-affiliated psychiatric hospital. They confirm 
that many clinical and administrative factors are associated with, 
or contribute to overall actual costs of psychiatric inpatient care. As 
expected, the dominant driver of costs (>90%) were per diem changes 
for hospitalization. In addition, however, 16 factors, not directly related 
to days hospitalized, also were significantly associated with higher total 
costs per person-year (Table 2). Notably this included sex, marital status, 
substance abuse, use of relatively expensive diagnostic tests, suspected 
poor adherence to previous treatment, and living non-independently. 
Most factors associated with costs appear to reflect relatively severe 
or complex illnesses, including treatment with clozapine, multiple 
antipsychotics, or ECT, specialist-consultations in hospital, having 
multiple, co-occurring general medical conditions, and receiving 
multiple non-psychotropic medicines. Diagnostically, patients with a 
primary, non-affective or schizoaffective psychotic disorder (Table 3) 
and those with psychotic features in any disorder, as well as suicidal 
behavior at any time were substantially more costly than subjects lacking 
such features. More years of lifetime illness, being older, unemployed, 
or requiring a supervised living situation after discharge also were 
associated with higher costs of care (Table 2, Figure 1). Notably, too, 
lower costs were associated with the index hospitalization as a first-
lifetime experience; this factor, too, probably reflects differences 
between subjects with recent, relatively acute illnesses and those with 
prolonged or recurrent illnesses. This interpretation also accords with 
striking differences in costs between subjects with chronic, psychotic 
disorders versus mood disorders (Table 3). 
In linear multivariate modeling, six factors remained associated 
independently and significantly with higher costs of hospital care, 
even with number of hospitalizations/year retained as an independent 
covariate (Table 4). These included diagnosis of a primary psychotic 
disorder (schizophrenia or schizoaffective disorder), more specialist 
consultations, treatment with ECT, clozapine, or multiple antipsychotic 
drugs, and being discharged to a supervised aftercare facility. 
Unsurprisingly, the same factors also correlated with days/year 
hospitalized. 
Again, we propose that most of the identified factors reflect more 
severe and prolonged illnesses that were relatively difficult to treat and 
required more time in hospital. It is notable, for example, that use of 
clozapine has been associated with savings in treatment costs in other 
circumstances notably, in comparisons of similarly severely ill subjects 
treated with this unusually effective drug versus others [56,57]. Here, 
however, use of clozapine evidently signals unusually severe and 
otherwise inadequately treatment-responsive illness. 
Although this study considered actual costs rather than insurance-
reimbursements, the observed costs at the study site were close to 
reported hospitalization costs of similarly diagnosed (mainly psychotic 
and bipolar disorder) subjects in other comparable settings [40,44]. The 
estimated total cost of hospital treatment was approximately $714/day 
of hospitalization over three years, with an average of 13 days/admission 
at the study site. These findings compare well with recent estimates 
of $793/day in hospital for comparably diagnosed subjects in other 
settings, during admissions averaging 10 days [39,40]. It is reassuring 
that the estimated total costs at the study site based on actual costs 
Rank Diagnosis Subjects (n)
Total Cost 
($/year)
Cost
95% CI
1 Schizoaffective 107 20,116 1661–23,571
2 Schizophrenia 77 18,125 14,151–22,099
3 Bipolar disorder 174 12,584 10,884–14,284
4 Major Depressive disorder 70 12,127 9447–14,807
5 Other Psychotic disorder 74 10,577 8705–12,449
6 Miscellaneous 34 9653 5848–13,548
7 Other Mood disorder 53 8092 6249–9935
––– All Subjects 589 13,797 12,695–14,899
Cost is thousands of dollars/year per person.  
Table 3: Total cost/person-year versus psychiatric diagnosis.
 
Figure 1: Annual cost of hospital care per person (thousands of dollars ± 95% 
confidence interval [CI]) with (black bars) versus without (gray bars) the stated 
factor being present, ranked by difference. All differences are highly statistically 
significant (all p<0.0002).  
Factor Slope [β] 95% CI t-score p-value
More hospitalizations/year 15.6 14.1–17.1 20.8 <0.0001
More consultations in hospital 4.37 3.07–5.68 6.58 <0.0001
Given ECT 14.2 6.14–19.4 5.48 <0.0001
Given clozapine 9.51 4.88–14.1 4.03 <0.0001
More antipsychotics in hospital 2.79 1.33–4.25 3.75 <0.0001
Supervised living after discharge 5.84 2.48–9.20 3.41 0.001
Nonaffective psychosis 4.04 1.25–6.85 2.84 0.005
Factors considered are based on findings in Table 1 [factors not included in the 
model were not significantly associated with cost]; model fit: F [7; 547 df] =103, 
p<0.00001. Costs are in thousands of dollars per person per year.  
Table 4: Multivariate linear regression model of factors associated with higher 
costs for psychiatric hospitalization.
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were similar to those estimated on the basis of insurers’ reimbursement 
rates used in other studies of the costs of clinical care [5,20,43]. It is 
also interesting to compare the costs of psychiatric hospitalization 
to those for common general medical disorders. For example, recent 
cost-estimates of hospitalization for stroke have averaged 21.8 (CI: 
4.70–39.0), and for a heart attack or comparable cardiac illness, 27.3 
(8.75–35.8) thousands of US dollars, or 2.3–2.9-times more than the 
average cost of psychiatric hospitalization at the present study site, 9.50 
(8.86–10.1) [58-60]. 
Many of the cost-associated factors identified appear to be related to 
longer-lasting or more severe illness, apparent treatment-resistance, and 
consequent disability. It is plausible that improved long-term treatments 
and clinical management that can limit acute symptoms as well as 
long-term morbidity and disability and provide supportive protection 
can reduce costs of psychiatric hospitalization overall [36,43]. Such a 
conclusion is hardly surprising, and efforts to improve the care of the 
severely and chronically mentally ill are a major focus of contemporary 
psychiatric research and practice. Nevertheless, such efforts should 
have high priority, with specific attention to both anticipated cost-
savings and cost-shifting. Less costly alternatives include practicable 
and well-tested options, such as partial-hospital, day-treatment, group 
homes, intensive outpatient care, and active community management 
programs. However, such programs vary widely in their accessibility 
and support by third-party payers, despite proven to be effective and 
less costly than hospitalization [36,37,43,61-64]. 
A major limitation of the present study is that the study sample, 
though large, only considered severe mental illnesses requiring 
inpatient care. Additionally, as the sample is from a single institution, 
it may not fully adequately represent other types of hospitals in other 
locations, although the costs encountered and lengths of hospitalization 
were similar to those reported in other recent studies, as noted [40,44]. 
A notable feature of the present analyses is their basis on actual costs 
rather than on insurer reimbursement rates, as have been used in other 
studies of costs of psychiatric treatment [5,20]. 
Conclusion
Not surprisingly, the present findings indicate that measures 
consistent with severe, chronic, and treatment-resistant psychotic 
illnesses were significantly associated with greater costs of inpatient 
psychiatric treatment, controlling for effects of hospitalization frequency. 
Specific factors identified encourage focusing on patient characteristics 
associated with greater costs and redoubled efforts to apply and improve 
cost-effective alternatives to psychiatric hospitalization. 
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